Compare NRG Energy Inc (NRG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Novo Nordisk A/S — how do they compare? NRG Energy Inc trades at $116.75 (market cap $25.15B), while Novo Nordisk A/S trades at $44.91 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 8× NRG Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NRG | NVO | |
|---|---|---|
Market Cap | $25.15B | $200.69B |
Sector | Utilities | Health |
52-Week High | $184.03 | $63.98 |
52-Week Low | $109.51 | $35.29 |
Enterprise Value | $49.10B | $215.49B |
Dividend Yield | 1.59% | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $119.64, up 0.52% with a bullish technical signal despite recent earnings misses. The stock shows strong profitability metrics including 26.77% ROE and 2.56% net margin, supported by $30.71B revenue in 2025. Recent developments include a transformative 1.2 GW Texas data-center power project and LS Power acquisition, driving long-term growth expectations. Cash flow trends show volatility with 2025 net cash flow of $3.83B followed by projected 2026 outflow of -$264M.
Wall Street maintains strong bullish sentiment with 69% buy ratings and $201.29 consensus target, representing 68% upside. Key risks include rising interest costs impacting earnings, elevated debt levels at 56.42% debt-to-asset ratio, and execution challenges with major capital projects. The data center expansion strategy offers significant growth potential but requires careful monitoring of capex and leverage management.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
